PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Amit Singal, MD, MS - It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration and Modern Therapeutics
Go online to PeerView.com/QYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the choice of regimens for patients with hepatocellular carcinoma (HCC) continues to expand with new standard-of-care therapies for advanced disease, and emerging innovative locoregional and multimodal strategies for early- and intermediate-stage disease, clinicians who treat liver cancer have increased opportunities to collaborate with colleagues and improve patient outcomes. Designed to guide professionals into a new era of team-based personalized care, this Seminars & Tumor Board activity features a multidisciplinary panel of experts who will link current science and treatment recommendations to practical guidance on therapeutic decision-making. Using case-based discussion, the expert panel will address a variety of clinical issues such as treatment selection, sequencing, and the integration of systemic therapy with locoregional management. It takes a team to provide the best care for your patients—participate in this activity to hear the latest on using collaborative strategies to optimize outcomes in HCC. Upon completion of this activity, participants should be better able to: Evaluate the efficacy/safety profiles and clinical roles of novel and emerging systemic therapy approaches for patients with advanced/metastatic HCC; Review the latest evidence on innovative strategies, including novel locoregional modalities, combinations of locoregional and systemic therapies, and perioperative/conversion approaches, for patients with HCC across the disease continuum; Develop contemporary, personalized management plans for patients with HCC that consider the available clinical evidence, expert/guideline recommendations, clinical trial opportunities, and patient-, disease-, and treatment-specific factors; and Implement best practices for multidisciplinary collaboration and care coordination when managing patients with HCC, including team-based strategies to maximize treatment efficacy, safety, tolerability, and patient quality of life.